Clinical Trials Logo

Filter by:
NCT ID: NCT04503122 Recruiting - Clinical trials for Paroxysmal Atrial Fibrillation

Baroreflex Sensitivity in Patients Undergoing Ablation of Atrial Fibrillation

BARO-AF
Start date: January 12, 2021
Phase:
Study type: Observational

Atrial fibrillation is the most common arrhythmia. The posterior surface of the left atrium is covered by an extensive network belonging to the autonomic nervous system that can be damaged during the ablation. The involvement of the autonomous nervous system in the genesis and maintenance of atrial fibrillation remains poorly understood. Baroreflex sensitivity is a non-invasive method assessing autonomous nervous system activity. The rate of atrial fibrillation recurrence after ablation is currently high and a better understanding of the mechanisms associated with recurrence is essential to improve selection of the patients who will benefit the most from this procedure. The aim of this study is to evaluate the association between the baroreflex sensitivity and atrial fibrillation recurrences and to analyze the prognostic contribution of the baroreflex measurement compared to other published criteria.

NCT ID: NCT04502927 Terminated - Stroke Clinical Trials

Measurements of Displacement Amplitude and Angular Velocities During Passive Extension of the Wrist and Hand Complex in Stroke Patients

PHYSIOHAND
Start date: March 10, 2020
Phase: N/A
Study type: Interventional

The main objective of this monocentric prospective study is to evaluate the amplitudes and angular velocities of extension of the hand and wrist joints during passive mobilization by a physiotherapist in healthy subjects and stroke patients with spastic hands. Secondary objectives: - To compare amplitude and angular velocity values between the group of stroke patients and the group of healthy volunteers, - To compare amplitude and angular velocity values according to the two types of mobilization (i,e, thumb or fifth finger), - To assess pain due to mobilization in stroke patients.

NCT ID: NCT04502771 Completed - Clinical trials for Intensive Care Unit Patients

Therapeutic Drug Monitoring of Antifungals in Intensive Care Units

Fungi-up
Start date: January 1, 2018
Phase:
Study type: Observational

Antifungals under- and over-dosing are frequently deplored in patients treated with antifungals and receiving recommended doses, mostly in critically-ill patients. This situation is well-described for antifungals from the azoles class mostly in patients with liver dysfunction or having concomitant drugs that may interact with azoles. This situation is less-described using echinocandins, although recent studies reported caspofungin underdosing for critically-ill patients. Considering that antifungals under-dosing was demonstrated to be associated with an increase in mortality, it is of utmost importance to analyse the relevance of therapeutic drug monitoring (TDM) for patients admitted in intensive care units (ICU). This will help to identify which patients are the more prone to antifungal under or over-dosing. Indeed, antifungals under-dosing may favour the development of clinical resistance to antifungals and increase mortality, whereas over-dosing may result in adverse events that may lead to treatment discontinuation.

NCT ID: NCT04502394 Recruiting - Clinical trials for Chronic Lymphocytic Leukemia

Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL

Start date: February 23, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

This study evaluates KRT-232, a novel oral small molecule inhibitor of MDM2, combined with acalabrutinib for the treatment of adults with Diffuse Large B-Cell Lymphoma and Chronic Lymphocytic Leukemia. Participants must be relapsed/refractory (having failed prior therapy)

NCT ID: NCT04502199 Not yet recruiting - Dysautonomia Clinical Trials

Dysautonomic Phenotype in Male Patients With MECP2 Mutation

MECP2BOYS
Start date: August 15, 2020
Phase:
Study type: Observational

Dysautonomic signs are well known among girls with a Rett Syndrom. Rett syndrom is caused by a MECP2 mutation in 95% of cases. We want to search dysautonomic signs among boys with a MECP2 mutations because they are less studied than the girls and they have more varied phenotypes.

NCT ID: NCT04501835 Completed - Clinical trials for Cardiac Implantable Electronic Device Infections

Assessment of Diagnostic and Therapeutic Practices for Cardiac Implantable Electronic Devices Suspected Infections in Nancy University Hospital

Start date: July 31, 2019
Phase:
Study type: Observational

The frequency of cardiac implantable electronic devices (CIED) is constantly increasing. Devices infections are one of the most serious complications in terms of morbidity and mortality. Although the frequency of cardiac implantable devices infections is difficult to derminate due to divergent definitions, cohort studies report a trend of increasing. The infection can be localized at the pocket of the implantation, at intravascular or intra-cardiac portion of leads. Infectious endocarditis defined by involvement of the intra-cardiac portion of leads is the most serious form. The diagnosis is based on clinical, biological and multimodal imagery data. Early diagnosis and specific management are necessary to reduce mortality and morbidity. Since the last European recommendations on infectious endocarditis in 2015, the HeartRythm Society of patient described an algorithm to treat CIED infections and extraction indications. However, in practice, management of CEID infections remains center-dependent and data from robust international studies are missing. The main objective of our study is to evaluate the management of CEID suspected infections and the prognosis at 1 year in terms of survival according to the methods of treatment at the Nancy University Hospital and to compare the treatment with the latest recommendations in force

NCT ID: NCT04501679 Completed - Prurigo Nodularis Clinical Trials

A Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN)

Start date: August 11, 2020
Phase: Phase 3
Study type: Interventional

The primary objective is to assess the efficacy of nemolizumab (CD14152) compared to placebo in participants greater than or equal to (>=) 18 years of age with prurigo nodularis (PN) after a 16-week treatment period.

NCT ID: NCT04501614 Active, not recruiting - Clinical trials for Ph+ Mixed Phenotype Acute Leukemia (MPAL)

A Study of Ponatinib With Chemotherapy in Children, Teenagers, and Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Start date: February 24, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

This study is about an anticancer drug called ponatinib which is a tyrosine kinase inhibitor given with chemotherapy to children, teenagers, and young adults up to 21 years of age with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia who have relapsed or are resistant to other treatment. The main aims of this study are to confirm the highest dose of ponatinib tablets and minitablet capsules that can be given to participants with acceptable side effects, and to evaluate if participant's leukemia achieves remission. Participants will take ponatinib tablets with chemotherapy. For participants who cannot swallow tablets or who are receiving less than a 10 mg dose, a capsule with small ponatinib minitablets inside will be provided. Participants will take ponatinib for 10 weeks in combination with chemotherapy (reinduction and consolidation blocks) and will be followed up for at least 3 years.

NCT ID: NCT04500535 Active, not recruiting - Lung Cancer Clinical Trials

A Study of Participants With Advanced Non-Small Cell Lung Cancer Treated With Nivolumab in France After at Least One Prior Chemotherapy-based Treatment by Lung Initiative on Sequence Therapy

LIST
Start date: September 28, 2020
Phase:
Study type: Observational

The purpose of this trial is to describe the following, for each cohort, in real world conditions in France: - The characteristics and treatment sequence of patients treated with nivolumab - The effectiveness of nivolumab treatment - The safety profile of nivolumab - Treatment patterns (e.g. duration of treatment, subsequent treatments) of nivolumab - The patient-reported outcomes (PRO) in patients treated with nivolumab, at baseline and during follow up using the EuroQoL-5D-3L

NCT ID: NCT04499846 Completed - Type II Diabetes Clinical Trials

Educational Intervention Targeting Statin Therapy and Compliance in Diabetic Patients

STADIA
Start date: June 11, 2020
Phase:
Study type: Observational

The objective of the study is to measure changes in compliance to statin therapy in patients with type 2 diabetes after an educational intervention. This intervention is part of the therapeutic education of the diabetic patient, carried out throughout the follow-up of his/her diabetes.